Document Detail


Cost-effectiveness in patients awaiting transplantation receiving intravenous inotropic support.
MedLine Citation:
PMID:  8223355     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cost-effectiveness, assessed in terms of cost/survivor and cost/additional day of survival, has been evaluated in two groups of patients awaiting cardiac transplantation: in six treated by mechanical support (mechanical bridge) and in 31 treated successfully by the addition of intravenous enoximone to previous existing inotropic support (pharmacological bridge). The mean cost per patient was $45,843, ranging from $38,326 in patients receiving pharmacological support to $84,683 in patients receiving mechanical support. The cost per patient transplanted after pharmacological support was $50,745. The mean cost per survivor at 1 year was $210,000 for all patients, ranging from $192,455 with pharmacological support to $254,000 with mechanical support. At 1 month, the cost per additional day of survival was higher (by 228%) in the mechanical support group than in the pharmacological support group.
Authors:
D Loisance; J C Sailly
Related Documents :
18401465 - Determining the cost-effectiveness of preventing cardiovascular disease: are estimates ...
7526475 - Cost effectiveness in the management of benign prostatic hyperplasia: italian data.
11758305 - Assessment of the treatment costs of extracorporeal shock wave therapy versus surgical ...
15585385 - Laparoscopic gastric bypass results in decreased prescription medication costs within 6...
11587465 - The effect of lidocaine/prilocaine cream on an experimental wound healing model.
9723825 - A new regimen for starting warfarin therapy in out-patients.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  European journal of anaesthesiology. Supplement     Volume:  8     ISSN:  0952-1941     ISO Abbreviation:  Eur J Anaesthesiol Suppl     Publication Date:  1993  
Date Detail:
Created Date:  1993-12-10     Completed Date:  1993-12-10     Revised Date:  2007-05-23    
Medline Journal Info:
Nlm Unique ID:  8804068     Medline TA:  Eur J Anaesthesiol Suppl     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  9-13     Citation Subset:  IM    
Affiliation:
Surgical Research Department, CHU H Mondor, Lille, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cost-Benefit Analysis
Enoximone / administration & dosage,  economics*
Heart Transplantation / economics*
Heart-Assist Devices / economics*
Humans
Injections, Intravenous
Prospective Studies
Shock, Cardiogenic / drug therapy,  therapy*
Chemical
Reg. No./Substance:
77671-31-9/Enoximone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  What is the place of the phosphodiesterase inhibitors?
Next Document:  Whether obesity should be treated.